Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$13.72
-0.26-1.86%
At close: Jan 21, 4:00 PM EST
$13.72
N/A
After Hours: 4:28 PM EST
Comments
Loading...
Crescent Biopharma Analyst Ratings and Price Targets | NASDAQ:CBIO | Benzinga
Crescent Biopharma Inc has a consensus price target of $27.17 based on the ratings of 6 analysts. The high is $35 issued by Guggenheim on January 21, 2026. The low is $22 issued by LifeSci Capital on June 18, 2025. The 3 most-recent analyst ratings were released by Guggenheim, HC Wainwright & Co., and Jefferies on January 21, 2026, August 27, 2025, and August 25, 2025, respectively. With an average price target of $28.67 between Guggenheim, HC Wainwright & Co., and Jefferies, there's an implied 108.94% upside for Crescent Biopharma Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Guggenheim
HC Wainwright & Co.
Jefferies
Wedbush
Stifel
1calculated from analyst ratings
Analyst Ratings for Crescent Biopharma
FAQ
What is the target price for Crescent Biopharma (CBIO) stock?
The latest price target for Crescent Biopharma (NASDAQ:CBIO) was reported by Guggenheim on January 21, 2026. The analyst firm set a price target for $35.00 expecting CBIO to rise to within 12 months (a possible 155.10% upside). 7 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Crescent Biopharma (CBIO)?
The latest analyst rating for Crescent Biopharma (NASDAQ:CBIO) was provided by Guggenheim, and Crescent Biopharma initiated their buy rating.
When was the last upgrade for Crescent Biopharma (CBIO)?
There is no last upgrade for Crescent Biopharma
When was the last downgrade for Crescent Biopharma (CBIO)?
There is no last downgrade for Crescent Biopharma.
When is the next analyst rating going to be posted or updated for Crescent Biopharma (CBIO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Crescent Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Crescent Biopharma was filed on January 21, 2026 so you should expect the next rating to be made available sometime around January 21, 2027.
Is the Analyst Rating Crescent Biopharma (CBIO) correct?
While ratings are subjective and will change, the latest Crescent Biopharma (CBIO) rating was a initiated with a price target of $0.00 to $35.00. The current price Crescent Biopharma (CBIO) is trading at is $13.72, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
